Outpatient Surgery Magazine

Special Outpatient Surgery Edition - Anesthesia - July 2019

Outpatient Surgery Magazine, providing current information on Surgical Services, Surgical Facility Administration, Outpatient Surgery News and Trends, OR Excellence and more.

Issue link: http://outpatientsurgery.uberflip.com/i/1139533

Contents of this Issue

Navigation

Page 6 of 66

Giving patients Tylenol (1,000 mg) and meloxicam (15 mg) as a pri- mary treatment and oxycodone as needed for breakthrough pain is at least as effective as opioids alone and avoids opioid-related side effects that can delay recovery and discharge. • Proactive PONV prevention. Administering IV dexamethasone 8 mg after anesthesia induction and a 5 hydroxytryptamine-3 (5HT3) antagonist, such as IV ondansetron 4 mg, at the end of procedures should be used at the minimum to prevent PONV in most patients. Transdermal scopolamine or IV haloperidol during surgery might be needed to settle the stomachs of high-risk patients. Long-acting 5HT3 antagonists such as palonosetron can prevent post-discharge nausea and vomiting, a key concern among providers in outpatient surgical facilities. • Expertise in regional blocks. Anesthesiologists advance pain man- agement by placing local and regional blocks that provide effective pain relief after major proce- dures. Single-shot adductor canal and popliteal-sciatic nerve blocks are helping to move knee replace- ments and major foot and ankle procedures to outpatient facili- J U L Y 2 0 1 9 • O U T PA T I E N T S U R G E R Y. N E T • 7

Articles in this issue

Links on this page

Archives of this issue

view archives of Outpatient Surgery Magazine - Special Outpatient Surgery Edition - Anesthesia - July 2019